Designed by BeiGene, Ociperlimab is an investigational monoclonal antibody designed to bind to TIGIT in an effort to combat cancer. Together with BeiGene we created an animation to support their groundbreaking work.
Sandostatin MOA
By
Jordan Maire
Working closely with Maven Communications, we developed a 3D MOA animation for Novartis illustrating the mechanism of action of Sandostatin LAR. Sandostatin LAR is indicated for the treatment of patients with symptoms associated with functional gastroenteropancreatic neuroendocrine tumors.
SONNET PLATFORM MOA
By
Jordan Maire
Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.
A FOCUS ON ALK-POSITIVE NON-SMALL CELL LUNG CANCER
By
admin
In partnership with Wedgewood Communications, XVIVO developed two videos for Takeda Oncology to discuss lung cancer mechanism of disease and treatments.
FROM MELANOCYTE TO MELANOMA
By
admin
Working with MELA Sciences, we designed this medical animation to help doctors and their patients …
THE ROLE OF SEROTONIN IN CARCINOID SYNDROME
By
admin
In this video, we will discuss tryptophan metabolism as applied to carcinoid syndrome in patients …
APOPTOSIS AND BCL-2
By
Jordan Maire
ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
GLEEVEC (IMATINIB) MOA
By
admin
Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling.
HULUC 63
By
admin
PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to …
TUMOR TREATING FIELDS
By
Jordan Maire
XVIVO and Novocure have teamed up to illustrate their breakthrough technology for the non-invasive treatment of solid tumors. Tumor Treating Fields, or TTFields, are alternating electric fields that disrupt and trigger death of cancerous cells.
Designed by BeiGene, Ociperlimab is an investigational monoclonal antibody designed to bind to TIGIT in an effort to combat cancer. Together with BeiGene we created an animation to support their groundbreaking work.
